Pathologist shortage and recruitment, lab competitiveness and AI algorithms drive digital pathology adoption In the most traditional definition of return-on-investment, Sam Terese, former CEO and president of Alverno Laboratories, would say that his company isn’t experiencing a strict apples-to-apples financial return on its digital pathology investment.

Terese likes to take a broader view of ROI that includes accuracy of tissue analysis, making his pathologists’ lives easier and better positioning his lab to be competitive to prospective employees and for customers. “It’s also about what will it do for patient care and how might it improve outcomes, how might it make us better in the marketplace, and how might it help us attract physicians, patients,” said Terese, whose laboratory serves

See Full Page